Search Medical Condition
Please enter condition
Please choose location from dropdown

Santiago de Compostela, Spain Clinical Trials

A listing of Santiago de Compostela, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (158) clinical trials

Phase

0.0 miles

Learn More »

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

0.0 miles

Learn More »

European Low and Intermediate Risk Neuroblastoma Protocol

LOW RISK STUDY The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations: Children aged 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2). Children aged 12 months with ...

Phase

0.0 miles

Learn More »

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

Diabetes mellitus and its complications represent nowadays an important issue in Public Health terms. The WHO expectations indicate that around 2025 the European population with diabetes will reach about 12%, and it has been estimated that the percent in the USA will be around 10% (King, 1995). The severe complications ...

Phase

0.0 miles

Learn More »

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

MPDL3280A (also called atezolizumab) is an immune check point inhibitor which targets programmed death-ligand 1 (PD-L1). Overexpression of PD-L1 prevents the immune system from eradicating cancerous cells as it blocks antigen recognition. MPDL3280A inhibits this interaction, allowing immune-mediated tumour cell killing.

Phase

0.0 miles

Learn More »

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)

Treatment of patients with ISR remains a challenge. Currently both drug-eluting stents (DES) and drug-coated balloons (DCB) are considered as the strategies of choice in this setting. However, data on the value of BVS in patients with ISR is scarce. BVS are very effective to inhibit neointimal proliferation and they ...

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease. Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following treatments for the duration of the study treatment ...

Phase

0.0 miles

Learn More »

A Treatment Study of Mucopolysaccharidosis Type IIIB

The study's primary objectives are to evaluate the safety and tolerability of BMN 250 administered to subjects with MPS IIIB via an ICV reservoir and catheter and to evaluate the impact of BMN 250 on cognitive function in patients with MPS IIIB as assessed by the Development Quotient.

Phase

0.0 miles

Learn More »

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children Known or Suspected to be Caused by Susceptible Gram-positive Organisms Including MRSA

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Phase

0.0 miles

Learn More »